Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence "MAbImprove," the GDR 3260 "Antibodies and therapeutic targeting," and the Grant Research program ARD2020 "Biotherapeutics" invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 - April 1, 2016 in Tours, France.
a Université François-Rabelais , Tours , France.|b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.|c Centre Hospitalo-Universitaire de Tours , Tours , France.
Guillaume
G
Desoubeaux
d The Antibody Society , Framingham , MA , USA.|e Reichert Biotechnology Consulting LLC , Framingham MA , USA.
Janice M
JM
Reichert
f MedImmune , Cambridge , UK.
Matthew
M
Sleeman
g City of Hope, Comprehensive Cancer Center , Duarte , CA , USA.
Karen L
KL
Reckamp
h Université d'Orléans , Orléans , France.|i University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM) , Cape Town , South Africa.
Bernhard
B
Ryffel
j Sanofi R&D , Chilly-Mazarin , France.
Jörg P
JP
Adamczewski
k Nektar Therapeutics , San Francisco CA , USA.
Theresa D
TD
Sweeney
l Université Catholique de Louvain, Louvain Drug Research Institute , Brussels , Belgium.
Rita
R
Vanbever
a Université François-Rabelais , Tours , France.|b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.|c Centre Hospitalo-Universitaire de Tours , Tours , France.
Patrice
P
Diot
m Harvard Medical School, Brigham and Women's Hospital , Boston , MA , USA.|n Lovelace Respiratory Research Institute , Albuquerque , NM , USA.
Caroline A
CA
Owen
o King's College, Sackler Institute of Pulmonary Pharmacology , London , UK.
Clive
C
Page
p PHENOMIN-TAAM CNRS, CIPA , Orléans , France.
Stéphanie
S
Lerondel
a Université François-Rabelais , Tours , France.|b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.|p PHENOMIN-TAAM CNRS, CIPA , Orléans , France.
Alain
A
Le Pape
a Université François-Rabelais , Tours , France.|b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.
Nathalie
N
Heuze-Vourc'h
D000280:Administration, Inhalation; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods / Q000639:trends; D006801:Humans; D012140:Respiratory Tract Diseases / Q000628:therapy*
D000911:Antibodies, Monoclonal
Antibody therapeutics; animal models; infectious diseases; inhalation; innovation; respiratory diseases